Public Company News

Kexing Biopharm Makes Its Debut at CPHI 2025, Followed by the 2025 International Pharmaceutical Cooperation High-End Forum, One of the Kexing Biopharm's Series of Globalization Activities in Shanghai

SHENZHEN, China, July 4, 2025 /PRNewswire/ -- Recently, Kexing Biopharm made a remarkable appearance at CPHI & PMEC China 2025 and successfully organized the 2025 International Pharmaceutical Cooperation High-End Forum, one of the Kexing Biopharm's series of globalization activities in Shanghai. ...

2025-07-04 16:26 3705

Invitation to presentation of Electrolux Group Q2 report

STOCKHOLM, July 4, 2025 /PRNewswire/ -- On 18th of July, Electrolux Group will publish the results for the second quarter of 2025, at approx. 07.00 CET. Media, investors and analysts are invited to a simultaneous video webcast and telephone conference on the same day following the release of the ...

2025-07-04 14:33 2004

Ping An Good Doctor Selected for First Batch of "Open-Source LLMs+" Innovation Application Cases, Showcasing Medical AI Scenario Implementation

HONG KONG and SHANGHAI, July 4, 2025 /PRNewswire/ -- The "Global Digital Economy Conference - Cloud-Intelligence-Computing Security Forum," also known as the third "SecGo Security Forum," was successfully held today inBeijing. The event was organized by the Global Digital Economy Conference Organ...

2025-07-04 14:14 2549

Herbalife's Aloin Identification Method for Aloe Vera Officially Recognized by AOAC INTERNATIONAL

Certified Method Enhances Global Botanical Quality and Safety HONG KONG, July 4, 2025 /PRNewswire/ -- Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced the Association of Official Analytical Collaboration (AOAC INTERNATIONAL)

2025-07-04 11:00 3847

Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China

* Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China * Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, J...

2025-07-04 08:30 3521

Visa's Security Roadmap calls time on outdated security as AI-driven scams surge in New Zealand

*  Visa is standing up to fraud in New Zealand with bold measures to fight the sharp rise in AI-powered fraud, including real-time analytics, biometric authentication, and mandating a move away from outdated security mechanisms. * New SMB Fraud Prevention Toolkit offers practical guidance, to...

2025-07-04 05:18 5459

Emeren Group Announces North America Management Change and Preliminary Q2 2025 Operating Results

NORWALK, Conn., July 3, 2025 /PRNewswire/ -- Emeren Group Ltd ("Emeren" or the "Company")(www.emeren.com ) (NYSE: SOL), a leading global solar project developer, owner, and operator, today announced a leadership transition within itsNorth America operations. Mr. Cameron "M...

2025-07-04 04:30 5506

Assembly Launches 'Assembly Control' to Elevate Brand Safety, Suitability, and Campaign Performance in Programmatic Media

First-of-its-kind custom solution prioritizes advertisers' brand safety and campaign performance NEW YORK, July 3, 2025 /PRNewswire/ -- Assembly, a leading media company part of the Stagwell (NASDAQ: STGW) challenger network, announced today the launch of Assembly Control, a proprietary brand s...

2025-07-03 22:00 2632

Creditsafe Realizes 234% ROI with BlackLine, Named Winner of 2025 Nucleus Research ROI Awards

Third-party recognition validates the measurable impact of BlackLine's AI-powered financial operations platform on global finance modernization LOS ANGELES, July 3, 2025 /PRNewswire/ -- BlackLine, Inc. (Nasdaq: BL), the future-ready financial operations platform for the Office of the CFO, today ...

2025-07-03 21:00 4540

NYSE Content advisory: Pre-Market update + June Jobs Report in focus

NEW YORK, July 3, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.    NYSE Content advisory: Pre-Market update + June Jobs Report in fo...

2025-07-03 20:56 3897

Zhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results

JILIN, China, July 3, 2025 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines inChina, toda...

2025-07-03 20:30 4559

Fangzhou Tops China's App Store Chart for Healthcare Apps

GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in theJune 2025 China AppStore Healthcare TOP100 Free APP Rankings with its Fangzhou Online Pharmacy App, according to a report by ...

2025-07-03 18:43 2221

Yunji Announces Changes in Management

HANGZHOU, China, July 3, 2025 /PRNewswire/ -- Yunji Inc. ("Yunji" or the "Company") (NASDAQ: YJ), a leading membership-based social e-commerce platform, today announced that Mr.Yeqing Cui, has resigned as Senior Financial Director and finance in charge of the Company for personal reasons, effecti...

2025-07-03 18:30 2136

So-Young Regains Compliance with Nasdaq Minimum Bid Price Requirement

BEIJING, July 3, 2025 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform inChina connecting consumers with online services and offline treatments, today announced that it has received a written compliance notification f...

2025-07-03 17:00 4135

Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy

HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispec...

2025-07-03 14:46 2347

Invitation to presentation of EQT AB's Half-year Report 2025

STOCKHOLM, July 3, 2025 /PRNewswire/ -- EQT AB's Half-year Report 2025 will be published on Thursday 17 July 2025 at approximately 07:00 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session. The presentation and a video link for the webcast will be ...

2025-07-03 13:41 1887

J&V Energy Wins Dual Honors at 2025 Asia Responsible Enterprise Awards for Environmental Leadership and Community Impact

BANGKOK, July 3, 2025 /PRNewswire/ -- J&V Energy Technology (6869-TW), a leader in integrated sustainable development and circular economy solutions in Taiwan, hasearned global recognition for its sustainable initiatives, securing two prestigious awards at the 2025 Asia Responsible Enterprise Awa...

2025-07-03 11:18 2633

World-Leading Breakthrough! Risen Energy's HJT Modules Hit Average 740Wp Mass Production with Record 26.61% Cell Efficiency

NINGBO, China, July 3, 2025 /PRNewswire/ -- A milestone in global heterojunction (HJT) photovoltaic technology! Risen Energy Co., Ltd. (Stock Code: 300118) today announced its self-developed Hyper-ion HJT modules have achieved a groundbreaking740Wp average mass-production power, setting a new in...

2025-07-03 10:00 4014

Eye Level Malaysia Ignites Learning Joy with Mid-Year Promo & Exclusive Block Sets!

KUALA LUMPUR, Malaysia, July 3, 2025 /PRNewswire/ -- Eye Level Malaysia, a leading name in supplemental education, is thrilled to announce its special Mid-Year Promo, designed to re-energize children's passion for learning as the school year progresses. From July 1st to July 31st, 2025, all new e...

2025-07-03 08:59 2861

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

* ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR  exon20ins * Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically significant and clinically meaningfulbenefits to patien...

2025-07-03 08:08 2256